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The autosomal recessive disorder lipoid proteinosis re-
sults from mutations in extracellular matrix protein 1
(ECM1), a glycoprotein expressed in several tissues (in-
cluding skin) and composed of two alternatively spliced
isoforms, ECM1a and ECM1b, the latter lacking exon 7
of this 10-exon gene (ECM1). To date, mutations that
either a¡ect ECM1a alone or perturb both ECM1 tran-
scripts have been demonstrated in six cases. However,
lipoid proteinosis is clinically heterogeneous with af-
fected individuals displaying di¡ering degrees of skin
scarring and in¢ltration, variable signs of hoarseness
and respiratory distress, and in some cases neurological
abnormalities such as temporal lobe epilepsy. In this
study, we sequenced ECM1 in 10 further unrelated
patients with lipoid proteinosis to extend genotype-
phenotype correlation and to add to the mutation data-
base.We identi¢ed seven new homozygous nonsense or
frameshift mutations: R53X (exon 3); 243delG (exon 4);
507delT (exon 6); 735delTG (exon 7); 785delA (exon 7);
892delC (exon 7) and 1190insC (exon 8), as
well as two new compound heterozygous mutations:
W160X/F167I (exon 6) and 542insAA/R243X (exons 6/7),
none of which were found in controls. The mutation
507delT occurred in two unrelated subjects on di¡erent
ECM1 haplotypes and may therefore represent a recur-
rent mutation in lipoid proteinosis. Taken with the pre-
viously documented mutations in ECM1, this study
supports the view that exons 6 and 7 are the most com-
mon sites for ECM1 mutations in lipoid proteinosis.
Clinically, it appears that mutations outside exon 7 are
usually associated with a slightly more severe muco-
cutaneous lipoid proteinosis phenotype, but neurologi-
cal features do not show any speci¢c genotype-pheno-
type correlation. Key words: genodermatosis/hyalinosis
cutis et mucosae/alternative splicing. J Invest Dermatol
120:345 ^350, 2003
L
ipoid proteinosis (LP), also known as hyalinosis cutis et
mucosae or Urbach-Wiethe disease (OMIM 247100), is
a rare autosomal recessive genodermatosis character-
ized by a variable degree of scarring and in¢ltration
of skin and mucosae (Hofer, 1973; Hamada, 2002). The
disorder usually presents in early infancy with hoarseness and
thickening of vocal cords. During childhood, the skin may be
easily damaged by minor trauma or friction, resulting in blisters
and varicelliform or acneiform scar formation. Subsequently,
in¢ltration of the mucosae may lead to respiratory di⁄culty,
especially in association with upper respiratory tract infection,
sometimes requiring tracheostomy (Ramsey et al, 1985). In
addition, recurrent episodes of in£amed parotid or submandibu-
lar glands, poor dental hygiene, and shortening of the
tongue with a thickened frenulum may also occur (Disdier et al,
1994; Aroni et al, 1998). In¢ltration of the skin may present
as grouped warty plaques on the dorsa of the hands and elbows.
In¢ltration of the eyelid margins results in beaded papules
referred to as moniliform blepharosis. Other extracutaneous
features may include epilepsy and neuropsychiatric abnor-
malities, sometimes in association with calci¢cation in the tem-
poral lobes or hippocampi (Friedman et al, 1984; Kleinert et al,
1987). Thus the clinical manifestations of lipoid proteinosis are
protean and may vary considerably between a¡ected individuals
(Hofer, 1973).
Reprint requests to: Dr John McGrath, Department of Cell and Mole-
cular Pathology, St John’s Institute of Dermatology, St Thomas’ Hospital,
Lambeth Palace Road, London SE1 7EH, England; E-mail: john.mc-
grath@kcl.ac.uk
Abbreviations: LP, lipoid proteinosis; ECM1, extracellular matrix
protein 1, Polymerase chain reaction PCR
Manuscript received October 22, 2002; revised November 13, 2002;
accepted for publication November 19, 2002
0022-202X/03/$15.00 . Copyrightr 2003 by The Society for Investigative Dermatology, Inc.
345
The molecular basis of lipoid proteinosis was recently shown
to result from mutations in the gene encoding extracellular ma-
trix protein 1 (ECM1) (Hamada et al, 2002). There are two alter-
natively spliced forms of ECM1, ECM1a and ECM1b, the latter
lacking exon 7 of this 10-exon gene. Both transcripts are ex-
pressed in skin and upper respiratory tract, although ECM1a is
also distributed more widely, including the placenta, heart, liver,
small intestine, lung, ovary, prostate, testis, skeletal muscle, pan-
creas and kidney (Smits et al, 1997). Previously, six di¡erent
homozygous mutations in ECM1 have been described, four that
a¡ect ECM1a (but not ECM1b), and two that are predicted to
disrupt both ECM1a and ECM1b.
In this study, we investigated ECM1 gene pathology in 10
further unrelated individuals with lipoid proteinosis to extend
the mutation spectrum in this genodermatosis and to help de¢ne
genotype-phenotype correlation.
MATERIALS AND METHODS
PCR ampli¢cation of genomic DNA and mutation detection
Following informed consent, DNA was extracted from peripheral blood
samples taken from a¡ected individuals, their parents and clinically
normal siblings (where possible) using a standard cold water lysis method.
Polymerase chain reaction (PCR) ampli¢cation of the ECM1 gene was
performed using eight pairs of primers spanning all 10 exons and situated
in £anking introns (Table I). For PCR ampli¢cation, 250 ng of genomic
DNAwas used as the template in an ampli¢cation bu¡er containing 6.25
pmol of the primers, 37.5 nmol MgCl2, 5 mmol of each nucleotide
triphosphate and 2.5 U Taq polymerase (Applied Biosystems,Warrington,
U.K.) in a total volume of 50 mL in an OmniGene thermal cycler (Hybaid,
Basingstoke, U.K.). The ampli¢cation conditions were 951C for 5 min,
followed by 38 cycles of 951C for 45 s, annealing temperature (see Table
I) for 45 s, 721C for 45 s. Aliquots (5 mL) of the PCR products were
analysed by 2.5% agarose gel electrophoresis. PCR products were then
puri¢ed using QIAquick PCR Puri¢cation Kit (Qiagen, Crawley, U.K.)
and sequenced directly using Big Dye labeling in an ABI 310 genetic
analyser (Applied Biosystems). Potential mutations were con¢rmed by
restriction endonuclease digestion or bi-directional sequencing and
assessed in up to 200 control chromosomes, selected to match the patients’
ethnic backgrounds. The control samples were selected from 3000 archival
DNA samples kept in the Department of Cell and Molecular Pathology at
St John’s Institute of Dermatology.
Identi¢cation of common nonpathogenic polymorphisms in
ECM1 To search for common sequence variants in ECM1, genomic
DNA from 40 control individuals was ampli¢ed using the PCR primers
and methods detailed above and then screened using heteroduplex
analysis, as described elsewhere (Ganguly et al, 1993). PCR products
displaying bandshifts were then investigated further by direct nucleotide
sequencing and subsequent calculation of allelic frequencies using
restriction endonuclease digestions, according to the manufacturer’s
recommendations (New England BioLabs, Hitchin, U.K.).
Keratinocyte cell culture Following informed consent, biopsies from
non-lesional, upper arm skin were taken under local anesthetic from two
a¡ected individuals (patients 1 and 2) and from the same site in control
subjects of similar age. The epidermis was separated from the dermis
using Dispase (Sigma-Aldrich, Poole, U.K.) in Dulbecco’s phosphate-
bu¡ered saline (Gibco-BRL, Paisley, U.K.) for 2 h at 371C, as described
previously (Bleck et al, 1999). Keratinocytes from the epidermal extract
were cultured, in the presence of a 3T3 feeder layer (Navsaria et al, 1994),
in Dulbecco’s modi¢ed Eagle’s medium (Gibco-BRL) and Ham’s F12
medium (Gibco-BRL) in a ratio of 3:1 (v/v) supplemented with 10%
fetal bovine serum (ICN Biomedicals, Hampshire, U.K.), 0.4 mg/ml
hydrocortisone (Sigma-Aldrich), 1010 M cholera toxin (Sigma-Aldrich),
10 ng/ml epidermal growth factor (Gibco-BRL), 5 mg/ml insulin (Gibco-
BRL), 1% penicillin/streptomycin (Sigma-Aldrich) and 1% pimaricin
(Autogenbioclear,Wiltshire, U.K.).
RNA extraction For RNA extraction from cultured keratinocytes, a
con£uent T75 £ask was used. RNA extraction with on-column DNase
digestion was performed using a commercial kit (RNeasy Midi Kits and
Rnase-Free DNase Set, Qiagen). RNA was quanti¢ed in a Model 6200
£uorimeter (Jenway, Dunmow, U.K.) using RiboGreen dye (Molecular
Probes Europe, Leiden, The Netherlands) and a standard curve ¢tting
created using ExcelTM (Microsoft, Reading, U.K.) for a range of known
control concentrations.
RT-PCR analysis For reverse transcription, two identical reactions for
each RNA sample were established comprising 5 mg DNase I-treated
RNA, 7 mL 5X M-MLV RT-bu¡er (Promega, Southampton, U.K.), 4 mL
10 mM dNTPs, 1 mL RNasin Riobonuclease inhibitor (Promega) and 1 mL
random primers (ICN). Reactions were incubated at 651C for 10 min and
then placed on ice. After cooling, 2 mL M-MLV reverse transcriptase (400
units) was added to one of the duplicate reactions, whereas 2 mLwater was
added to the other (negative control). Samples were then incubated at 421C
for 90 min and then stored at ^ 201C. PCR for house-keeping genes L32
and GAPDH were used to compare the quantity of the cDNA template
and to exclude genomic contamination. A pair of primers for RT-PCR
across the sites of the 243delT and 507delT mutations in patients 1 and 2
(see Results) comprised: forward primer 50 -TACAGGACAGAGGCA
GCTGA-30 (nucleotides 81^100; GenBank XM_002030, with initiation
codon ATG as nucleotide 1-2-3), reverse primer 50 -GAACTCGGCCT
CACAGAATC-30 (nucleotides 747^728). The reverse primer for RT-PCR
was placed within exon 7. Therefore, ECM1a but not ECM1b was
speci¢cally ampli¢ed by this RT-PCR reaction using these primers.
The size of the expected RT-PCR product was 667-bp. The ampli-
¢cation conditions were 951C for 5 min, followed by 38 cycles of
951C for 45 s, 601C for 45 s, 721C for 45 s. For the PCR reactions,
1 mL of the solution with the ¢rst strand cDNAwas used as a template in
a 50 mL reaction containing 6.25 pmol of each primers, 37.5 nmol of
MgCl2, 5 mmol of each nucleotide and 2.5 U ofTaq polymerase (Applied
Biosystems) in an OmniGene thermal cycler (Hybaid). The RT-PCR
products were subcloned into a PCR-compatible cloning vector (TOPO
TA Cloning Kit, Invitrogen, Paisley, U.K.) and sequenced directly using
Big-Dye labeling in an ABI 310 genetic analyser (Applied Biosystems).
RESULTS
Clinical Patient 1 was a 38-year-old Thai male (Fig 1a^c). He
had severe hoarseness since birth, as well as extensive skin
scarring and in¢ltration with prominent hyperkeratotic erosions
on both legs. He had a history of occasional convulsions and
aura in keeping with temporal lobe epilepsy. He had a similarly
a¡ected 19-year-old brother (Fig 1e). One other a¡ected sibling
died aged 34-years from acute-on-chronic upper airway
obstruction. His parents were not known to be consanguineous
but came from the same rural district.
Table I. Intronic genomic primers used for PCR ampli¢cation of ECM1
Exon no. Forward primer (50-30) Reverse primer (50-30) Annealing temp. (1C) Product size (bp)
1 agctgggactgagtcatggc taaaggctccactggcctag 62 416
2/3 tcctacactcttgatctcca ggtgtcaacaggatccatag 60 622
4/5 cagtgaccctccaggtttct cagagcccaccgtcttgtct 60 484
6 agccttgagaagcaggagga agtgaacgggacctgaggtt 60 671
7 ttatctgcctgcccagtgtc acatggatggatggactggc 60 548
8 cacatcaacagttgcctcct ggcatcttctggcatcagat 60 499
9 agttgcctagtccttcccca aggccaggtcagagtgaaga 60 408
10 aatccagctgtgcaaggcag gtaatgagtgttcagatggg 62 469
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Patient 2 was a 30-year-old Thai female, unrelated to patient 1.
She had mild hoarseness since early childhood but minimal
skin signs apart from a few beaded papules on both upper
eyelids (Fig 1d), starting aged 5-years, and slight thickness of the
frenulum with restricted tongue movement. She also su¡ered
from occasional episodes of collapse with transient loss of
consciousness suggestive of petit mal epilepsy. There was no
family history and no reported consanguinity, although the
parents originated from the same province in Southern
Thailand.
Patient 3 was a 23-year-old Indian male who had hoarseness
and progressive in¢ltrated papules and scarring (starting on the
face) since infancy. He also had pock-like scarring on the face
and upper trunk, warty in¢ltrated plaques in both groins and
thickening of his oral mucosa. He had no history of epilepsy but
a computed tomography scan showed bilateral temporal lobe
calci¢cation. He had a younger sister with LP and the parents
were known to be ¢rst cousins.
Patient 4 was a 16-year-old Japanese male, for whom full
clinico-pathological details have been described recently
(Nagasaka et al, 2000). Brie£y, he had hoarseness, refractory
temporal lobe epilepsy, blisters, scars, eyelid papules and
extensive papular skin in¢ltration. He also had radiographic
signs of temporal lobe calci¢cation. His parents were non-
consanguineous.
Patient 5 was a 3-year-old Canadian male from an Iranian
family, in which the parents were ¢rst cousins. He had a hoarse
voice since birth, and scattered skin crusts and erosions
particularly on his upper trunk and face starting in the second
year of life. These lesions were followed by scarring that
resembled hydroa vacciniforme. There were no neurological
abnormalities. No other family members were a¡ected.
Patient 6 was a 14-year-old Turkish female from a
consanguineous family. A 4-year-old sister was also a¡ected.
Clinico-pathological details of this family have been published
recently (Kaya et al, 2002). Brie£y, she had hoarseness since birth
and progressive varicelliform scars and warty skin papules. She
also showed radiographic temporal lobe calci¢cation.
Patient 7 was a 17-year-old American female from an Iranian
family. Her parents were third cousins. She developed erosive
skin lesions and hoarseness from infancy. The skin erosions
resolved as linear and cribriform scarring. Periorbital in¢ltrated
papules were ¢rst noted at the age of 9 years, and have
progressively increased in number.
Patient 8 was a 5-year-old Italian female born to non-
consanguineous parents. She developed hoarseness during the
¢rst few months of life. At the age of 3 years, she started to get
post-traumatic crusting and scarring on her face as well as signs
of beaded eyelid papules. To date, there have been no other
signi¢cant skin or mucosal changes.
Patient 9 was a 2-year-old Canadian male of central European
origin. His parents were non-consanguineous. He had hoarseness
since birth, as well as progressive skin scarring and in¢ltration.
Although his mother was clinically normal, his maternal
grandmother was reported to have LP (further details not
available). No other family members were a¡ected.
Patient 10 was a 53-year-old Japanese male. He had severe
hoarseness since early childhood and progressive skin scarring and
in¢ltration. The degree of skin thickening in some sites was
particularly prominent and warty skin plaques were present on the
elbows and knees. Several papules were also noted on the eyelid
margins. No neurological features had been noted at any stage. He
had an 80-year-old brother with similar skin features. However,
the brother had very severe laryngeal in¢ltration and had a
tracheostomy inserted at the age of 67 years. Their parents were not
known to be consanguineous but came from the same region.
Development of a PCR-based mutation detection strategy
To facilitate detection of pathogenetic mutations in LP, we
designed genomic DNA primers to amplify exons 1^10 of
ECM1, with primers sited 450 bp away from the intron-exon
borders. Primer sequence details, the optimized ampli¢cation
conditions and the expected sizes of PCR products are indicated
inTable I.
Identi¢cation of two common missense polymorphisms in
ECM1 Heteroduplex analysis of ampli¢ed DNA from normal
controls identi¢ed similar bandshifts in several of the PCR
products spanning exon 6 and exon 8. Sequencing revealed two
point mutations, a C4T transition at nucleotide 389 in exon 6
that converts a threonine residue (ACG) to methionine (ATG),
and a G4A substitution at nucleotide 1243 in exon 8 that
changes glycine (GGT) to serine (AGT). These sequence variants
altered cut sites for the restriction endonucleases Bsm I and BsiE I,
respectively. For the 389C/T polymorphism, the major allele was
C (0.61) and the minor allele was T (0.39); 72 chromosomes
(control from mixed ethnic backgrounds) were examined. For
the 1243G/A polymorphism, the major allele was G (0.53) and
the minor allele was A (0.47); 64 chromosomes were examined.
Delineation of pathogenic ECM1 mutations in LP
Sequencing of genomic DNA in the 10 unrelated patients with
LP disclosed pathogenic mutations in each case, as detailed in
Table II. Cases 1^7 were homozygous for small internal
deletion/insertion mutations that lead to frame-shift and
downstream premature termination codons: three of these
mutations occured within the alternatively spliced exon 7. The
mutation 507delT (Fig 2) was identi¢ed in two unrelated
patients but was shown to have arisen on di¡erent haplo-
types: patient 1 was homozygous for methionine at amino
acid position 130, whereas patient 6 was homozygous for
threonine (see details of intragenic exon 6 polymorphism
above). Case 8 was a compound heterozygote for a frameshift/
Figure1. Clinical features of LP demonstrating skin in¢ltration and
scarring. (a) warty, in¢ltrated plaques on the extensor aspects of the fore-
arms and elbows (case 1); (b) in¢ltration of the lips and tongue and thick-
ening of the frenulum (case 1); (c) scarring and hyperkeratotic erosions on
the lower limb (case 1); (d) warty papules on the upper eyelid (moniliform
blepharosis) (case 2); (e) pitted, acneiform scarring on the cheek (a¡ected
brother of case 1).
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nonsense combination of mutations. Case 9 was a compound
heterozygote for a nonsense/missense combination of mutations.
Case 10 was homozygous for a nonsense mutation. All nonsense
and frameshift mutations were veri¢ed by restriction endo-
nuclease digestion and/or bi-directional nucleotide sequencing,
con¢rmed in heterozygous family members, and excluded in
80^120 control chromosomes. At least 80 of the control
chromosomes used to exclude the frameshift or nonsense
mutations were accurately matched with the ethnic background
of the case of LP harboring that particular mutation. To exclude
the possibility of the missense mutation F167I being a non-
pathogenic polymorphism, this sequence change was excluded
in 200 ethnically matched control chromosomes. This control
group comprised Caucasian Southern European DNA. These
new mutations, and the previously documented mutations in
other patients with LP, are illustrated in Fig 3.
Genotype-phenotype correlation for ECM1 mutations in
LP In general, patients with mutations in exon 7 tended to
have milder upper respiratory tract abnormalities and less skin
scarring/in¢ltration compared to patients with mutations in
other parts of the gene. However, the di¡erences were often
subtle and evidence for intrafamilial variability was seen in
families with more than one a¡ected member (patients 1, 3 and
6) as well as interfamilial variability for unrelated patients with
the same mutation (patients 1 and 5). Direct comparisons
between some a¡ected individuals were di⁄cult because of the
di¡erent ages of the patients and the typical progressive nature
of the skin scarring and in¢ltration with increasing age. The
mildest clinical signs were noted in patient 2, who was
homozygous for the mutation 243delG in exon 4.
RT-PCR analysis helps explain genotype-phenotype
disparity In cultured keratinocyte cDNA from patients 1 and
2, RT-PCR identi¢ed multiple di¡erent PCR bands compared
to a single 667-bp band in the control sample (Fig 4a).
Subcloning and direct sequencing disclosed multiple aberrant
mutant transcripts, most of which were out-of-frame. However,
evidence for restoration of the open reading frame was noted for
one mutant transcript in patient 2 with the clinically mild
phenotype. Speci¢cally, sequencing of a 484-bp band revealed
evidence for aberrant splicing with in-frame skipping of exons 3
and 4 leading to deletion of 61 amino acids from the cysteine-free
domain (Fig 4b). No other in-frame transcripts corresponding to
the remaining multiple di¡erent PCR bands from both samples
were identi¢ed.
DISCUSSION
In this study, we have identi¢ed 11 new mutations in the ECM1
gene in patients with LP. Details of these and the previous ECM1
Table II. New pathogenic ECM1 mutations detected
in this study
Patient Mutation (s) Exon (s) Veri¢cation
1 507delT/507delT 6 Hpa II
2 243delG/243delG 4 Hpy178 III
3 785delA/785delA 7 Fau I
4 892delC/892delC 7 Seq
5 507delT/507delT 7 Hpa II
6 735delTG/735delTG 6 Hpy188 I
7 1190insC/1190insC 8 Bgl I
8 542insAA/R243X 6/7 Hpa II / Seq
9 W160X/F167I 6/6 Mnl I / SfaN I
10 R53X/R53X 3 Seq
Seq¼ sequencing
Figure 2. Identi¢cation of a recurrent ECM1 mutation in LP,
507delT, in exon 6. (a) direct sequencing of exon 6 of ECM1 in patient 1
reveals a 1-bp deletion of T at nucleotide 507 (507delT) (GenBank
XM_002030).This mutation leads to a frameshift and premature stop codon
23-bp downstream. (b) veri¢cation of the mutation 507delT by restriction
endonuclease digestion with Hpa II (New England BioLabs, Hitchen,
U.K.).Wild-type PCR product (^/^) spanning exon 6 and £anking introns
(671-bp) is digested into products 313, 243, 91 and 24-bp in size (the smal-
lest band is not visible), consistent with three cut sites forHpa II. In patients
homozygous for the mutation 507delT (þ /þ ), the PCR product is
further digested into fragments 313, 224, 91, 24 and 19-bp in size (smallest
two bands are not visible), as the mutation introduces a fourth cut site for
this enzyme within the 243-bp fragment. In individuals heterozygous for
507delT (þ /^), six digested fragments (313, 243, 224, 91, 24 and 19-bp)
are present. Products resolved by 3% agarose gel electrophoresis.
(MW¼fX174 HaeIII molecular weight marker.)
1 2 3
785delA
892delC
4 5 8 9 10
507delT243delG
1019delA
Q276X W359X
Q346X
1163-bp deletion
501insC
6
735delTG
542insAA/R243X
W160X/F167I
7
1190insC
ATG TGA
R53X
Figure 3. Illustration of the positions of 11 new mutations and the previous ECM1 gene mutations. New mutations are depicted below and pre-
viously reported mutations above the gene structure. Most mutations comprise frameshift or nonsense mutations located in exon 6 or the alternatively
spliced exon 7. The homozygous mutation 507delT has been detected in two unrelated individuals on di¡erent ECM1 haplotypes. Most of the mutations
in LP patients are homozygous (double arrow head).
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mutations are illustrated in Fig 3. The combined data thus far
suggest that the majority of mutations occur in exon 7. This exon
is alternatively spliced and we have previously shown that frame-
shift mutations in exon 7 lead to ablation of the ECM1a tran-
script, but not the shorter ECM1b transcript that normally lacks
this exon (Hamada et al, 2002). Outside exon 7, most other muta-
tions are found in exon 6. Collectively, these two exons contain
24/32 of the mutated ECM1 alleles delineated thus far.These ¢nd-
ings have implications for mutation detection strategies in LP and
we recommend initial sequencing of exon 7, then exon 6, and
then the remainder of the ECM1 gene in the investigation of
any new patients with this genodermatosis.
Homozygous nonsense or frameshift mutations in exon 6
are predicted to a¡ect both full-length ECM1a and ECM1b
transcripts, whereas ECM1b should be una¡ected for similar
types of mutation in exon 7 (Hamada et al, 2002). This provides
an opportunity to review the phenotype of LP patients harbor-
ing ECM1a/ECM1b genotype pathologies. Clinical assessment
of our series of patients suggests that individuals with mutations
in exon 7 have a slightly milder phenotype than individuals with
mutations outside exon 7. These observations are true for respira-
tory and skin manifestations of LP, but do not appear to relate to
neuropathological abnormalities such as temporal lobe epilepsy
and/or brain calci¢cation. Indeed, a calcium-binding domain has
been identi¢ed in exon 7 of ECM1 and this might explain the
lack of speci¢c genotype-phenotype correlation for these particu-
lar features (Bhalerao et al, 1995; Smits et al, 1997). A further di⁄-
culty in comparing clinical signs in di¡erent patients relates to
the patients’ age. Typically in LP, there is an initial phase of skin
blisters and crusting followed by later changes of progressive scar-
ring and skin in¢ltration. Thus, comparing signs in an infant
with those in an adult is likely to re£ect more than just the inher-
ent ECM1genotype. Likewise, it is evident that trauma does con-
tribute to the severity or extent of skin changes since many of the
scars and in¢ltrated skin plaques are induced or exacerbated by
physical trauma. Nevertheless, the observations that patients with
mutations in exon 7 have a similar (if very slightly milder) phe-
notype to other cases with mutations elsewhere does provide sup-
port for the ECM1a transcript having a more signi¢cant overall
biological role in human skin and mucosae when compared to
the ECM1b transcript.
Interestingly, our patient with the mildest clinical features had
a homozygous frameshift mutation in exon 4 that would be pre-
dicted to disrupt both ECM1a and ECM1b. However, we found
evidence for partial rescue of the mutant transcript through in-
frame skipping of the exon containing this mutation and the ad-
jacent upstream exon, giving a shorter transcript lacking 61 ami-
no acids. This part of the protein is upstream from most of the
known functional domains of ECM1 (e.g., ligand and calcium
binding and predicted protein loops) (Bhalerao et al, 1995; John-
son et al, 1997; Smits et al, 1997). Similar skipping of exons con-
taining frameshift mutations has been described in other
genodermatoses to account for unexpectedly mild phenotypes
(McGrath et al, 1999).Thus, the e¡ects of RNA processing are im-
portant in evaluating genotype-phenotype correlation in LP.
The mutation 507delT in exon 6 was identi¢ed in two unre-
lated patients and was shown to have arisen on di¡erent ECM1
haplotypes. Speci¢cally, the patients had di¡erent amino acid
polymorphisms at codon 130 in the same exon harboring the
pathogenic mutations. Review of the nucleotide sequence sur-
rounding the deleted T reveals palindromic runs of multiple C
or G repeats, suggesting that this part of the ECM1 gene might
be prone to slipped mispairing during replication, as reported
for several other recurrent mutations throughout the genome
(Denoyelle F et al, 1997; Schimmenti et al, 1997).
Nearly all the ECM1 mutations in LP reported thus far are
homozygous, re£ecting that most cases of this rare genodermato-
sis occur in consanguineous families. However, in this study we
identi¢ed two compound heterozygote mutations. One of these
patients had a nonsense/frameshift combination of mutations but
the other patient harbored nonsense/missense mutations. The
missense mutation F167I was excluded as a common or rare poly-
morphism by screening 200 control chromosomes. Although this
amino acid change represents substitution of one hydrophobic
neutral amino acid by another, F167 is a conserved residue (pre-
sent in mouse ECM1 sequence) and the amino acid change does
markedly alter the size of the amino acid side chain.The substitu-
tion occurs near the start of the ¢rst tandemly-duplicated domain
of ECM1 (regions of the protein that have homology to albu-
min-binding loops) and forms part of a highly conserved FPPG
amino acid sequence characteristic of these tandem duplications
(Bhalerao et al, 1995; Smits et al, 1997). Nevertheless, the precise
consequences of this missense mutation on ECM1 protein func-
tion are not yet known. Indeed, the biological function of ECM1
is only starting to become clear, largely through elucidation of
ECM1 as the pathogenic gene in LP. Initially, ECM1 had been
shown to inhibit bone mineralization, to contribute to epidermal
di¡erentiation, and to stimulate angiogenesis (Smits et al, 2000;
Deckers et al, 2001; Han et al, 2001). However, demonstration of
mutations in LP has emphasized the signi¢cance of ECM1, parti-
cularly the ECM1a isoform, in the physiology and biology of the
dermis. It is likely that ECM1 contributes to protein binding of
interstitial collagens, basement membrane collagens and glycosa-
minoglycans since lack of the protein (as occurs in LP) results in
Figure 4. RT-PCR and subcloning across the sites of the 243delG
and 507delTmutations reveals evidence for partial rescue of mutant
transcript in the patient with mild disease. In control ampli¢ed cDNA
(lane C), a single band of 667-bp is present. By contrast, in the ampli¢ed
cDNA from patient 1 (genomic mutation 507delT) and 2 (genomic muta-
tion 243delG) (lane P1 and P2, respectively), multiple PCR bands are pre-
sent. Subcloning revealed numerous out-of-frame aberrantly spliced
products. However, subcloning of one band (n) in P2 (patient with mild
disease clinically) revealed evidence for partial rescue of the mutant tran-
script with skipping of exons 3 and 4 (b) resulting in an in-frame deletion
of 61 amino acids (183-bp). (MW¼fX174 HaeIII molecular weight
marker.)
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massive reduplication of basement membrane (Olsen et al, 1988) as
well as the clinical features of scarring and skin in¢ltration. How-
ever, thus far there are no reports detailing the speci¢c protein^
protein interactions of ECM1 in skin or other tissues.
In this study, we have elucidated the molecular basis of LP in 10
unrelated patients, identi¢ed two common intragenic poly-
morphisms, and developed a mutation detection strategy for
screening DNA from patients with this genodermatosis. The
results demonstrate the mutation spectrum in LP and identify
some of the practical di⁄culties in correlating genotype with
phenotype.
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